PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1463770
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1463770
Key Highlights
The intubation tubes market generated a value of USD 2,727.6 million in 2023, and it will increase to USD 4,294.4 million, with more than 6.5% CAGR, by 2030.
The increasing prevalence of road accidents and trauma is a key industry driver. There has been a substantial increase in the count of road accidents resulting in death over the years.
As per the WHO, around 1.5 million people die in road accidents annually.
A substantial emotional trauma to victims' families and economic loss are the extra burdens that come along with such accidents.
Major accidents led to substantial trauma to patients, who then necessitated surgical intervention or immediate treatment, thus boosting the requirement for intubation tubes.
The outbreak of SARS-CoV-2 resulted in exponential growth in industry revenue. The outbreak of coronavirus had a substantial positive impact on this industry.
There was a quick increase in the count of seriously ill patients, for whom intubation was essential in emergencies because one of the main problems that came along with the ailment was difficulty in breathing.
Intubation tubes are an accepted means of delivering breathing support to patients with novel coronavirus.
Key Insights
The regular category accounted for the largest share of the industry in 2023, of 40%. This can be attributed to the increasing volume of surgical measures because of the surging incidence of respiratory diseases.
The reinforced category will propel at a high compound annual growth rate in the years to come. This will be because of the increasing count of patients suffering from neurological conditions needing surgeries and the rising count of facial surgeries and road accidents.
The orotracheal category was the largest contributor to the industry in 2023, with approximately 75% share. Orotracheal is the most common insertion route of these tubes because of its comfort for patients.
Orotracheal is extensively accepted in treating apneic and severely ill patients ailing from multisystem diseases and severe injuries.
Emergency treatment accounted for the largest share in 2023, of approximately 55%. This can be attributed to the increasing incidence of emergencies like cardiopulmonary arrest, accidents, respiratory distress, and obstruction of the airways.
Therapy will propel at a significant CAGR in the years to come. This will be mainly because of the surging count of surgical measures, most of which necessitate intubation tubes for managing the airways.
North America was the largest contributor to the industry in 2023, with a share of approximately 60%.
The growth in North America is due to the robust healthcare services and infrastructure; well-established reimbursement policies, and rising acceptance of technologically improved devices by the medical industry.
APAC is likely to propel at the fastest compound annual growth rate during this decade. This is because of the increasing level of pollution leading to respiratory conditions, surging elderly populace, and substantial incidence of cardiopulmonary illnesses, all of which eventually result in the growing requirement for surgeries.
The intubation tubes industry is very fragmented as well as competitive. Players in this market are continuously involved in strategic initiatives like new product launches, acquisitions, collaborations, and technological improvements, to enhance their presence.